FDA has heeded a recommendation by scientific experts and agreed that “associated distress” may be a co-primary endpoint for clinical trials of drugs intended to treat low sexual interest, desire, and/or arousal disorders, in the place of number of “satisfying sexual events.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?